Navigation Links
Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
Date:11/28/2007

TOKYO, November 28 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the Phase III clinical trial programme for its fentanyl sublingual spray (AD 923), an opioid analgesic for the treatment of cancer breakthrough pain.

The clinical trial authorisation (CTA) covers two multi-centre pivotal Phase III efficacy studies followed by an open label safety study. Patient enrolment in the UK is expected to commence before the end of the year and will be the subject of a separate announcement. Applications have been made in other European countries and further patient recruitment will be initiated as soon as approval is received from the relevant local regulatory body.

This first CTA in a major European country will also trigger the receipt of a project milestone payment under the AD 923 Licence Agreement signed with Mundipharma in June 2006.

Mr Shinichi Tamura, President & CEO of Sosei, said: "Receipt of our first Phase III CTA represents an important milestone in the evolution of Sosei and the continuing progress of the AD 923 development programme. We look forward to enlisting our first patients in the trial".

Notes to Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About AD 923

AD 923 is an optimised, sublingual formulati
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
2. Sosei Announces Update on Phase I Trials for SD118
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Deer Path of Huntley ... Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. on ... Parkway in Huntley, Illinois, serves adults with physical disabilities between the ... include Valentine's Day treats, games and sweetheart-themed karaoke. , For more ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Inc. (Nasdaq: CRTX ) announced today that it ... 27, 2009. At the special meeting of stockholders, Cornerstone,s ... sale of shares of Cornerstone,s common stock to Chiesi Farmaceutici ... May 6, 2009, between Cornerstone and Chiesi Farmaceutici SpA. , ...
... June 11 The Campaign for Tobacco-Free Kids applauds U.S. Senator ... gives the U.S. Food and Drug Administration (FDA) authority to ... tobacco marketing and sales to kids. The U.S. Senate ... has approved similar legislation, and Congress is expected to quickly ...
... 11 The Campaign for Tobacco-Free Kids applauds U.S. Senators ... historic legislation that gives the U.S. Food and Drug Administration ... crack down on tobacco marketing and sales to kids. ... The House has approved similar legislation, and Congress is ...
... Tobacco-Free Kids applauds U.S. Senator Bill Nelson for voting today ... Drug Administration (FDA) authority to regulate tobacco products, including the ... kids. The U.S. Senate approved the bipartisan bill 79 ... Congress is expected to quickly send a final bill to ...
... Tobacco-Free Kids applauds U.S. Senator Sherrod Brown for leading the ... gives the U.S. Food and Drug Administration (FDA) authority to ... tobacco marketing and sales to kids. The U.S. Senate ... House has approved similar legislation, and Congress is expected to ...
... , June 11 The Campaign for Tobacco-Free Kids ... today to approve historic legislation that gives the U.S. Food ... the authority to crack down on tobacco marketing and sales ... 79 to 17. The House has approved similar legislation, ...
Cached Medicine News:Health News:Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock 2Health News:Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock 3Health News:Senator McCaskill Votes to Protect America's Kids From Tobacco 2Health News:Senators Carper and Kaufman Vote to Protect America's Kids From Tobacco 2Health News:Senator Bill Nelson Votes to Protect America's Kids from Tobacco 2Health News:Senator Brown Leads Fight to Protect America's Kids from Tobacco 2Health News:Senators Mikulski and Cardin Vote to Protect America's Kids From Tobacco 2
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
(Date:1/22/2015)...  Uroplasty, Inc. (NASDAQ: UPI ), a medical device ... to treat voiding dysfunctions, today reported financial results for ... Global revenue for the Company,s Urgent ®  PC ... quarterly revenue record, as compared to $3.9 million in ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... , , , , ... WX ), a,leading pharmaceutical, biotechnology, and medical-device research ... announced that it had been selected for the Deloitte Technology ... to receive this award,for the past six years. The Deloitte ...
... Pa., Dec. 21 West Pharmaceutical Services, Inc. (NYSE: ... unanimously decided on December 15, 2009, to ask shareholders to ... starting in 2012. Currently, the Company,s board has three classes ... term. The proposed amendment will not shorten the current ...
Cached Medicine Technology:West Announces Intention to Elect Entire Board Annually 2
... The SpectraMax 190 spectrophotometer is ideal for ... For aqueous solutions, our patented* PathCheck sensor ... in each microplate well, and normalizes the ... corrected absorbance is within 5% of the ...
The Clearblue Easy Ovulation Test detects the surge of "luteinizing hormone in your urine, which usually happens 24 to 36 hours before you ovulate (release an egg). That means youll know the 2 best ...
... In the fast-paced world of echo ... make a real difference in your ability ... developed Xcelera Echo Lab Management, a unique ... providing the tools your department needs to ...
These products are primarily for use with paediatric patients and for patients with difficult veins....
Medicine Products: